

Lubka T Roumenina

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7152449/lubka-t-roumenina-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110
papers

6,313
citations

39
h-index

79
g-index

131
ext. papers

8,090
ext. citations

6.5
avg, IF

5.81
L-index

#	Paper	IF	Citations
110	Complement System Part I - Molecular Mechanisms of Activation and Regulation. <i>Frontiers in Immunology</i> , 2015 , 6, 262	8.4	714
109	Complement System Part II: Role in Immunity. <i>Frontiers in Immunology</i> , 2015 , 6, 257	8.4	501
108	Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. <i>Nature Reviews Nephrology</i> , 2012 , 8, 643-57	14.9	392
107	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. <i>Kidney International</i> , 2012 , 82, 454-64	9.9	360
106	Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 859-67	12.7	320
105	Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. <i>PLoS Medicine</i> , 2011 , 8, e1001013	11.6	204
104	Complement factor H related proteins (CFHRs). <i>Molecular Immunology</i> , 2013 , 56, 170-80	4.3	159
103	Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. <i>Blood</i> , 2013 , 122, 282-92	2.2	155
102	Endothelium structure and function in kidney health and disease. <i>Nature Reviews Nephrology</i> , 2019 , 15, 87-108	14.9	149
101	C1q and its growing family. <i>Immunobiology</i> , 2007 , 212, 253-66	3.4	143
100	Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. <i>Blood</i> , 2011 , 117, 1340-9	2.2	142
99	Alternative complement pathway assessment in patients with atypical HUS. <i>Journal of Immunological Methods</i> , 2011 , 365, 8-26	2.5	119
98	Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. <i>Blood</i> , 2009 , 114, 2837-45	2.2	119
97	Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. <i>Biochemistry</i> , 2006 , 45, 4093-104	3.2	108
96	A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. <i>Blood</i> , 2012 , 119, 4182-91	2.2	107
95	Context-dependent roles of complement in cancer. <i>Nature Reviews Cancer</i> , 2019 , 19, 698-715	31.3	99
94	Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. <i>JCI Insight</i> , 2018 , 3,	9.9	87

93	Heme: Modulator of Plasma Systems in Hemolytic Diseases. <i>Trends in Molecular Medicine</i> , 2016 , 22, 200-213		81
92	Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. <i>Blood</i> , 2015 , 125, 2359-69	2.2	79
91	Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. <i>Journal of Immunology</i> , 2012 , 189, 3528-37	5.3	78
90	Antibody polyreactivity in health and disease: statu variabilis. <i>Journal of Immunology</i> , 2013 , 191, 993-9	5.3	74
89	Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 2053-65	12.7	74
88	Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. <i>Journal of Immunology</i> , 2015 , 194, 5129-38	5.3	73
87	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. <i>Cancer Immunology Research</i> , 2019 , 7, 1091-1105	12.5	68
86	Endothelial cells: source, barrier, and target of defensive mediators. <i>Immunological Reviews</i> , 2016 , 274, 307-329	11.3	63
85	Loss of DGK α induces endothelial cell activation and death independently of complement activation. <i>Blood</i> , 2015 , 125, 1038-46	2.2	63
84	Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions. <i>Journal of Biological Chemistry</i> , 2007 , 282, 26696-26706	5.4	62
83	Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. <i>American Journal of Transplantation</i> , 2012 , 12, 1938-44	8.7	61
82	Mutational analyses of the recombinant globular regions of human C1q A, B, and C chains suggest an essential role for arginine and histidine residues in the C1q-IgG interaction. <i>Journal of Immunology</i> , 2004 , 172, 4351-8	5.3	58
81	Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 1603-1613	12.7	56
80	The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. <i>Blood</i> , 2014 , 123, 121-5	2.2	54
79	An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. <i>Journal of Immunology</i> , 2013 , 191, 912-21	5.3	54
78	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. <i>Kidney International</i> , 2017 , 92, 1232-1241	9.9	52
77	P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 6280-6285	11.5	51
76	Functional complement C1q abnormality leads to impaired immune complexes and apoptotic cell clearance. <i>Journal of Immunology</i> , 2011 , 187, 4369-73	5.3	47

75	Role of Ca ²⁺ in the electrostatic stability and the functional activity of the globular domain of human C1q. <i>Biochemistry</i> , 2005 , 44, 14097-109	3.2	43
74	Heme interacts with c1q and inhibits the classical complement pathway. <i>Journal of Biological Chemistry</i> , 2011 , 286, 16459-69	5.4	42
73	Functional and structural insight into properdin control of complement alternative pathway amplification. <i>EMBO Journal</i> , 2017 , 36, 1084-1099	13	40
72	Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. <i>Seminars in Thrombosis and Hemostasis</i> , 2010 , 36, 641-52	5.3	37
71	Existence of different but overlapping IgG- and IgM-binding sites on the globular domain of human C1q. <i>Biochemistry</i> , 2006 , 45, 9979-88	3.2	35
70	Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. <i>Journal of Biological Chemistry</i> , 2015 , 290, 25343-55	5.4	31
69	A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 1665-77	12.7	29
68	A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. <i>Kidney International</i> , 2017 , 92, 876-887	9.9	29
67	Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3706-14		28
66	Genetics of hemolytic uremic syndromes. <i>Presse Medicale</i> , 2012 , 41, e105-14	2.2	26
65	Interaction of the globular domain of human C1q with Salmonella typhimurium lipopolysaccharide. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2008 , 1784, 1271-6	4	26
64	Complement C1q-target proteins recognition is inhibited by electric moment effectors. <i>Journal of Molecular Recognition</i> , 2007 , 20, 405-15	2.6	25
63	Iron ions and haeme modulate the binding properties of complement subcomponent C1q and of immunoglobulins. <i>Scandinavian Journal of Immunology</i> , 2007 , 65, 230-9	3.4	25
62	B cells and cancer: To B or not to B?. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	25
61	Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis. <i>Frontiers in Immunology</i> , 2018 , 9, 179	8.4	24
60	Hemolysis Derived Products Toxicity and Endothelium: Model of the Second Hit. <i>Toxins</i> , 2019 , 11,	4.9	23
59	Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1. <i>Frontiers in Immunology</i> , 2018 , 9, 3008	8.4	23
58	Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 2899-907	4.3	21

57	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. <i>Frontiers in Immunology</i> , 2018 , 9, 2260	8.4	21
56	Anti-Factor B Antibodies and Acute Postinfectious GN in Children. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 829-840	12.7	20
55	Heme induces human and mouse platelet activation through C-type-lectin-like receptor-2. <i>Haematologica</i> , 2021 , 106, 626-629	6.6	20
54	Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions. <i>Transfusion Clinique Et Biologique</i> , 2019 , 26, 116-124	1.9	19
53	Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. <i>American Journal of Hematology</i> , 2020 , 95, 456-464	7.1	19
52	Site-specific N-glycosylation analysis of soluble Fcγreceptor IIIb in human serum. <i>Scientific Reports</i> , 2018 , 8, 2719	4.9	18
51	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. <i>Genome Medicine</i> , 2020 , 12, 86	14.4	17
50	Analysis of protein missense alterations by combining sequence- and structure-based methods. <i>Molecular Genetics & Genomic Medicine</i> , 2020 , 8, e1166	2.3	16
49	Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes. <i>Molecular Medicine</i> , 2016 , 21, 1002-1010	6.2	16
48	Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling. <i>Journal of Immunology</i> , 2016 , 197, 3669-3679	5.3	16
47	Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis. <i>Kidney International</i> , 2021 , 99, 581-597	9.9	15
46	Autoantibodies Against C3b-Functional Consequences and Disease Relevance. <i>Frontiers in Immunology</i> , 2019 , 10, 64	8.4	14
45	Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgA ₁ Antibody. <i>American Journal of Kidney Diseases</i> , 2015 , 66, 331-6	7.4	14
44	Complement System: Promoter or Suppressor of Cancer Progression?. <i>Antibodies</i> , 2020 , 9,	7	13
43	Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS). <i>Methods in Molecular Biology</i> , 2014 , 1100, 237-47	1.4	13
42	Complement C3 is a novel modulator of the anti-factor VIII immune response. <i>Haematologica</i> , 2018 , 103, 351-360	6.6	13
41	Mechanism and functional implications of the heme-induced binding promiscuity of IgE. <i>Biochemistry</i> , 2015 , 54, 2061-72	3.2	11
40	Physiological and therapeutic complement regulators in kidney transplantation. <i>Current Opinion in Organ Transplantation</i> , 2013 , 18, 421-9	2.5	11

39	A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 1524-31	15.4	11
38	Anti-factor H autoantibodies assay. <i>Methods in Molecular Biology</i> , 2014 , 1100, 249-56	1.4	9
37	Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme. <i>Molecular Immunology</i> , 2019 , 111, 205-208	4.3	8
36	Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation. <i>Frontiers in Immunology</i> , 2020 , 11, 1684	8.4	8
35	Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy. <i>Frontiers in Immunology</i> , 2021 , 12, 680567	8.4	8
34	Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. <i>Cancer Immunology Research</i> , 2021 , 9, 909-925	12.5	7
33	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. <i>Cancer Immunology Research</i> , 2021 , 9, 891-908	12.5	7
32	Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis. <i>Frontiers in Immunology</i> , 2020 , 11, 1772	8.4	5
31	The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction. <i>Transfusion Medicine Reviews</i> , 2019 , 33, 225-230	7.4	5
30	Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. <i>Molecular Immunology</i> , 2009 , 47, 290-7	4.3	5
29	Coagulome and the tumor microenvironment: an actionable interplay.. <i>Trends in Cancer</i> , 2022 ,	12.5	5
28	The receptor for advanced glycation end products is a sensor for cell-free heme. <i>FEBS Journal</i> , 2021 , 288, 3448-3464	5.7	5
27	Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
26	Detection of Autoantibodies to Complement Components by Surface Plasmon Resonance-Based Technology. <i>Methods in Molecular Biology</i> , 2019 , 1901, 271-280	1.4	4
25	A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the SSL7 Protein. <i>Frontiers in Immunology</i> , 2018 , 9, 2822	8.4	4
24	Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival. <i>Inflammation</i> , 2017 , 40, 117-122	5.1	3
23	Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H. <i>Pediatric Nephrology</i> , 2019 , 34, 533-537	3.2	3
22	B cells and complement at the forefront of chemotherapy. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 393-394	19.4	2

21	Clinical and functional consequences of anti-properdin autoantibodies in patients with lupus nephritis. <i>Clinical and Experimental Immunology</i> , 2020 , 201, 135-144	6.2	2
20	Complement Detection in Human Tumors by Immunohistochemistry and Immunofluorescence. <i>Methods in Molecular Biology</i> , 2021 , 2227, 191-203	1.4	2
19	C1q+ macrophages: passengers or drivers of cancer progression.. <i>Trends in Cancer</i> , 2022 ,	12.5	2
18	C3dg-CR3 interaction in erythrophagocytosis. <i>Blood</i> , 2015 , 126, 828-9	2.2	1
17	Exploration du complément : actualité 2012. <i>Revue Francophone Des Laboratoires</i> , 2012 , 2012, 31-37	0	1
16	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression		1
15	Ex Vivo Complement Activation on Endothelial Cells: Research and Translational Value. <i>Trends in Molecular Medicine</i> , 2021 , 27, 418-421	11.5	1
14	Chronic histiocytic intervillitis: manifestation of placental alloantibody-mediated rejection. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 225, 662.e1-662.e11	6.4	1
13	The Benefits of Complement Measurements for the Clinical Practice. <i>Methods in Molecular Biology</i> , 2021 , 2227, 1-20	1.4	1
12	Complement factor H: a guardian within?. <i>Kidney International</i> , 2021 , 100, 747-749	9.9	1
11	Test for Measuring Complement Attack on Endothelial Cells: From Research to Bedside.. <i>Frontiers in Immunology</i> , 2022 , 13, 860689	8.4	1
10	Glomerulonephritis With Isolated C3 Deposits as a Manifestation of Subtotal Factor I Deficiency. <i>Kidney International Reports</i> , 2019 , 4, 1354-1358	4.1	0
9	Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis. <i>Frontiers in Immunology</i> , 2021 , 12, 690821	8.4	0
8	Plasma C3d levels as a diagnostic marker for complete complement factor I deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 749-753.e2	11.5	0
7	Terminal complement without C5 convertase?. <i>Blood</i> , 2021 , 137, 431-432	2.2	0
6	Contribution of the C1q Polypeptide Chains in the Recognition of CRP. <i>Biotechnology and Biotechnological Equipment</i> , 2005 , 19, 122-125	1.6	
5	Registration of the Interaction Between C1q Human Complement Derivatives and Immunoglobulins by Elisa Role of the Solid Phase. <i>Biotechnology and Biotechnological Equipment</i> , 2004 , 18, 116-120	1.6	
4	ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A «KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES» (KDIGO) CONTROVERSIES CONFERENCE. <i>Nephrology (Saint-Petersburg)</i> , 2018 , 22, 18-39	0.4	

- 3 Detection of Anti-C3b Autoantibodies by ELISA. *Methods in Molecular Biology*, **2021**, 2227, 133-139 1.4
- 2 Complement C3 Deposition on Endothelial Cells Revealed by Flow Cytometry. *Methods in Molecular Biology*, **2021**, 2227, 97-105 1.4
- 1 FP076ATYPICAL HEMOLYTIC UREMIC SYNDROME - WHY THE KIDNEY?. *Nephrology Dialysis Transplantation*, **2018**, 33, i74-i74 4.3